Fig. 1.

Prevalence of specific HLAs in US controls of European ancestry and transplant recipients of European ancestry who had kidney failure secondary to IgAN in the native kidney, including these with recurrent and nonrecurring disease. Patients of European ancestry with kidney failure secondary to IgAN (n = 169) [combining 54 recurrent IgAN and 115 nonrecurring IgAN] were compared to controls from European ancestry (n = 15,740) from US donors of stem cell transplantation. DQ typing was only available for 149 patients with native kidney failure secondary to IgAN, including 48 recurrent IgAN and 101 nonrecurring disease. Another comparison was performed between recurrent and nonrecurring IgAN. Since 6 HLAs were compared, the Bonferroni-corrected cut-off of 0.008 was considered significant. Of note, DR15 and DQ6 are in linkage disequilibrium to form a common haplotype. IgAN, IgA nephropathy; HLA, human leukocyte antigen.